Development of dPCR-based molecular MRD for acute myeloid leukemia
About the session
Measurable residual disease (MRD) is the most important post-treatment predictor of outcome in patients with adult myeloid leukemia (AML). While flow cytometry-based methods for MRD detection are well-established clinically, molecular methods of MRD detection are still in research development. The use of digital PCR for highly sensitive monitoring of AML-associated mutations in patients on a variety of treatment plans will be discussed, as well as its predictive value for relapse. Bone marrow and cell-free DNA-based MRD will be explored. We will also demonstrate the value of multiplexing assays for simultaneous detection of multiple mutations in limiting patient samples.